Published

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Scientific reports
Date: 2021-11-18
Source: PubMed
DOI: 10.1038/s41598-021-01811-4
PubMed: 34795334

Authors

Rootman JM Kryskow P Harvey K Stamets P Santos-Brault E Kuypers KPC Polito V Bourzat F Walsh Z

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Microdosing Wellbeing Other

Citation graph

0 referenced DOIs found in stored source metadata. 5 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 Evaluating psilocybin for the management of depression: a literature review2026-08-02 Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development2026-07-03 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.2021-11-18

Related papers

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29 Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentClinicalTrials.gov · 2025-10-02